Bliss GVS Pharma
- Market cap
- ₹ 6,640 Cr.
- P/E
- 50.2x
- P/B
- 5.7x
- 52-week range
- 118 – 739.9
- ROE
- 12%
- ROCE
- 17%
- Dividend yield
- 0.2%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products, other healthcare products, and therapeutic index. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, oral solids, and others. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, NOVOGLIP-5, GVZOLE, and DOXYCYCLINE.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Bliss GVS Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)50.2 against a typical 34.3: pricier than most peers (1st = cheapest).156th of 220
- Sales growth+38.2% against a typical +15.6% from a year earlier.41st of 197
- Profit growth+15.9% against a typical +18.9% from a year earlier.89th of 160
- Share price, 3 months+43.1% against a typical −0.5%.15th of 200
- Size₹ 6,640.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).49th of 199
Latest announcements
Exchange filings and their impact on the company.
- Anupam Rasayan group completed takeover of Bliss GVS and erstwhile promoters were moved to public category.
Bliss GVS Pharma said control passed to Anupam Rasayan India and Mates Visa Consultancy on September 28, 2026 after the May 23 share purchase deal and open offer were completed. The board on the same day noted reclassification of the erstwhile promoters to the public category. No deal value or future plans were given in this filing, but the company now has a new strategic promoter group.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Withdrawn | — | 5 Jun 2026 |
| ICRA | [ICRA]A- Rating Watch with Developing Implications/[ICRA]A2+ Rating Watch with Developing Implications | — | 2 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 5 Jun 2026 | Withdrawn | was Crisil B/Stable/Issuer Not Cooperating (Withdrawn) | — | CRISIL | ₹ 160 Cr. | |
| 2 Jun 2026 | Reaffirmed | [ICRA]A- /[ICRA]A2+ → [ICRA]A- Rating Watch with Developing Implications/[ICRA]A2+ Rating Watch with Developing Implications | — | ICRA | ₹ 100 Cr. | |
| 8 Apr 2026 | Reaffirmed | [ICRA]A- /[ICRA]A2+ | — | ICRA | ₹ 100 Cr. | |
| 2 Sep 2025 | Reaffirmed | Crisil BBB+ | — | CRISIL | ₹ 160 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 1 Oct 2026 | Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| 12 Aug 2026 | Financial Results/Other business matters | Please find enclosed herewith intimation regarding pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, August 12, 2026, at the registered office of the Company to consider and approve, inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. |
| 12 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 10 Feb 2026 | Financial Results/Dividend | To consider and approve the Unaudited financial results for the period ended December 31, 2025 and the interim dividend, if any, for the financial year 2025-2026 |
| 6 Nov 2025 | Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2025 |
| 29 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| Expenses | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 201 | 183 | 213 | 209 |
| Operating Profit | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 43 | 35 | 44 | 76 |
| OPM % | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% | 18% | 16% | 17% | 27% |
| Other Income | 13 | 5 | −24 | 4 | 5 | 15 | 12 | 35 | 8 | 16 | 11 | 10 |
| Interest | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 | 2 | 1 |
| Depreciation | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 10 |
| Profit before tax | 59 | 40 | −4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 |
| Tax % | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% | 30% | 39% | 18% | 32% |
| Net Profit | 43 | 29 | −5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 |
| EPS in Rs | 4.05 | 2.64 | −0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.2 | 3.36 | 4.72 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 7%
- TTM
- 21%
- 10 Years
- 5%
- 5 Years
- 14%
- 3 Years
- 23%
- TTM
- 29%
- 10 Years
- 16%
- 5 Years
- 40%
- 3 Years
- 84%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Bliss GVS Pharma | ₹ 652.75 | ₹ 6,640 Cr. | 50.2x | 5.7x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Narsimha Shibroor Kamath
- Chief Executive Officer, Managing Director
- Rahul Adakmol
- Chief Executive Officer
- Deepak Sawant
- Chief Financial Officer
- Aditi Himanshu Bhatt
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.